SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as the community eagerly awaits imminent Phase 3 REGAL trial results, fueling strong conviction around GPS immunotherapy's potential for "curative" outcomes in AML. Investors are overwhelmingly bullish, dismissing persistent bearish takes from some while anticipating a significant short squeeze and potential for substantial buyout offers for its promising pipeline.

Aventus Network

Aventus Network ($AVT) is gaining attention following its formal DAO incorporation in the UAE and the appointment of a strategic advisor for regional expansion, alongside developments for its enterprise-focused Aventus Cloud. The community is actively discussing AVT's potential for a significant breakout, highlighting its low market capitalization, Polkadot integration, and enterprise-grade technology as key indicators, while closely monitoring for increased trading volume.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending with high anticipation for its R2 launch event, propelled by a recent analyst upgrade and the strong performance of its software division, as the community actively debates the stock's future potential amid rising energy costs boosting EV adoption.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as the broader market experiences a significant rebound, primarily fueled by statements suggesting the Middle East conflict is nearing an end. However, this rally sparks intense community debate, with many traders questioning the legitimacy of the 'peace' narrative and labeling it an algo-driven 'fake pump' detached from current geopolitical realities.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending as its engaged community actively embraces the "What's UpDog?" meme, fueling bullish sentiment and highlighting its long-term presence on Solana with locked liquidity and a listing on the Jupiter Strict List.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its robust oncology pipeline delivers significant news, including positive Phase 3 data for a breast cancer drug and promising lung cancer therapy results, which has garnered a Goldman Sachs upgrade and shifted community focus towards its potential beyond COVID-19 vaccines.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending amidst strong anticipation for its upcoming earnings report, as the community actively discusses the potential for a significant short squeeze fueled by high short interest and optimistic outlooks on holiday sales. Bullish sentiment is further bolstered by discussions around the retailer's strategic turnaround and its undervalued real estate assets, countering broader concerns within the retail sector.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a significant Q4 EPS beat, signaling a pivotal shift to profitability driven by accelerating MIPLYFFA revenue growth, which the community believes makes the "hugely undervalued" stock ripe for a substantial re-rating with anticipated EMA approval on the horizon.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending following its substantial $250 billion commitment to US connectivity and strategic partnerships in fiber and satellite technology. The community is actively discussing strong earnings, a bullish long-term outlook, and significant shareholder return plans, positioning it as a key value play in the telecom sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Heightened speculation surrounding a potential acquisition, particularly from major pharmaceutical players, is driving conversation around CRISPR Therapeutics. The community is also closely watching for further updates on Casgevy's market performance and the company's gene-editing pipeline, which is seen as benefiting from a supportive regulatory landscape for innovative therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Japan Exchange Group Sees Short Interest Decrease from 98,000 shares to 37,700 shares. $JPXGY https://www.marketbeat.com/stocks/OTCMKTS/JPX

View a list of the top-rated stocks to buy listed on the OTC Markets Exchanges (OTCMKTS) at MarketBeat.

MarketBeat

What Investors Must Know About Over-the-Counter (OTC) Stocks

Zapier

JAPAN EXCHANGE/ADR

Japan Exchange Group Sees Short Interest Decrease from 98,000 shares to 37,700 shares. 